Fibe Aims for ₹1,500 Crore IPO, Eyes Billion-Dollar Valuation by 2026...
08 Aug, 2025
Anthem Biosciences Limited, one of the leading Contract Research and Innovation Service Providers (CRISP), is set to raise the amount of ₹3,395 crore through its upcoming IPO (Initial Public Offering). The IPO will entirely be an OFS (Offer for Sale), allowing the investors the opportunity to exit their holdings while the company continues to grow. With the valuation of 5.96 crore shares by the existing shareholders, this IPO is said to pave the way for the company's expansion and strengthen its foothold in the biopharma industry. The IPO aims to increase the company’s visibility and solidify its position in the CRDMO sector.
The Anthem Biosciences IPO will comprise an issue of ₹3,395 crore, with the value of each share set between ₹540 and ₹570 per share. The offering will entirely be an offer-for-sale (OFS), stating that all proceeds will be received by the selling shareholders, not by the company itself. The IPO is set to open for subscriptions on July 14, 2025 and close on July 16, 2025, with the finalization date regarding the allotment of shares on July 17, 2025, with a tentative listing date of July 21, 2025, on both the BSE and NSE. This IPO will further support the company’s expansion into international markets, including the U.S., Europe and Japan.
Preparing for the upcoming IPO, Anthem Biosciences has made some changes in its board to facilitate its smooth transition into a public limited company, to make India its domicile under local regulatory requirements and to ensure full compliance with SEBI’s regulations. In order to attract a wider pool of local investors, the company remains domiciled in India alongside increasing its global visibility. This restructuring supports the company’s goal of expanding its customer base internationally while allowing it to simultaneously maintain a strong presence in the Indian market.
Anthem Biosciences, continuing with its consistent and impressive financial growth in recent years, has reported a 30% increase in revenue, which reached ₹1,930.29 crore. The Profit After Tax (PAT) for FY 2025 stood at ₹451.26 crore. This indicates a positive and healthy growth rate of 23% over the previous year. Reportedly, the company’s EBITDA margin of 36.81% further demonstrates its operational efficiency and profitability. With its strong debt-to-equity ratio of 0.05 in its debt sheets, which is comparatively lower than many of its competitors with significant levels, highlights the company’s financial discipline and ability to generate robust cash flow from operations with this low leverage.
With a clientele of over 550 customers, which includes both small biotech firms and large multinational pharmaceutical companies. Its ability to provide end-to-end services has played a major role in maintaining its strong foothold in the market and has allowed it to cater to a wide range of customers, spread across 40+ countries throughout the globe. As one of the fastest-growing CRDMOs in India, Anthem provides a wide and comprehensive range of services, including the manufacturing of active pharmaceutical ingredients, drug discovery and development. Anthem holds a distinct advantage over other companies in the CRDMO space.
The Anthem Biosciences’ upcoming IPO is set to be a milestone of great importance in India’s rapidly growing biopharmaceutical sector and is said to be a game-changer for the company. With its strong financial trajectory, innovative business model and robust market position, Anthem Biosciences is set to continue its leadership in the CRDMO space and is up for a major expansion. The IPO will provide profitable exits for early investors and open the door for the company to focus on its technological advancement and scale up its global operations. This IPO with ₹3,395 crore in potential funds attracts significant international investor interest to the Indian CRDMO space.
Read more :
